- Home
- HSHP vs LXRX Comparison
HSHP vs LXRX Comparison
Compare HSHP & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.69
Company Overview
Basic Information| Metric | HSHP | LXRX |
|---|---|---|
| Founded | 2021 | 1995 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.5M | 547.4M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HSHP | LXRX |
|---|---|---|
| Price | $12.47 | $1.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 370.2K | ★ 2.3M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 6.27% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $27.67 | N/A |
| Revenue Next Year | N/A | $22.16 |
| P/E Ratio | $34.01 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $4.29 | $0.32 |
| 52 Week High | $14.95 | $1.83 |
Technical Indicators
Market Signals| Indicator | HSHP | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 62.33 |
| Support Level | $7.17 | $1.08 |
| Resistance Level | $14.95 | $1.83 |
| Average True Range (ATR) | 0.43 | 0.13 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 0.40 | 71.62 |
Price Performance
Historical Comparison HSHP
LXRX
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.